Short Description Juvenescence co‑founder financing late‑stage longevity startups.
Description Former biotech analyst Dr. Greg Bailey teamed with Jim Mellon to create Juvenescence, a holding company that has invested $300 million across cell therapy, senolytics, and AI‑generated small molecules. Juvenescence’s portfolio includes LyGenesis (organ regeneration via lymph‑node scaffolding) and AgeX Therapeutics. Bailey’s strategy mirrors ‘big pharma’ pipelines but focused exclusively on aging biology. He is a familiar face at JP Morgan Healthcare Week and writes op‑eds urging pension funds to allocate to gerotherapeutics.